Trial Profile
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Apr 2023 Planned End Date changed from 15 Apr 2023 to 15 May 2024.
- 12 May 2022 Planned End Date changed from 15 Apr 2022 to 15 Apr 2023.